Multiple Sclerosis Journal

Papers
(The H4-Index of Multiple Sclerosis Journal is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition959
COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021177
Exercise and lifestyle physical activity recommendations for people with multiple sclerosis throughout the disease course150
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis70
COVID-19 in multiple sclerosis: The Dutch experience70
Multiple sclerosis management during the COVID-19 pandemic60
A smartphone sensor-based digital outcome assessment of multiple sclerosis51
Neurofilament levels are associated with blood–brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis50
COVID-19 in people with multiple sclerosis: A global data sharing initiative48
Vaccinations in patients with multiple sclerosis: A Delphi consensus statement39
MSVirtual 2020 – Poster Abstracts38
Aggressive multiple sclerosis (1): Towards a definition of the phenotype38
In vivo imaging of chronic active lesions in multiple sclerosis37
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study36
Synaptic and complement markers in extracellular vesicles in multiple sclerosis36
Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients36
Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres36
Macular ganglion cell–inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis35
Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression35
Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network34
Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms34
Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension33
Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome32
The relative contributions of obesity, vitamin D, leptin, and adiponectin to multiple sclerosis risk: A Mendelian randomization mediation analysis32
Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient31
MOG-IgG1 and co-existence of neuronal autoantibodies30
Wearable technologies to measure clinical outcomes in multiple sclerosis: A scoping review30
Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MO30
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies29
Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis29
Childhood obesity and multiple sclerosis: A Mendelian randomization study29
Which exercise and behavioural interventions show most promise for treating fatigue in multiple sclerosis? A network meta-analysis29
0.052777051925659